Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + XELOX + RT in locally advanced gastric adenocarcinoma
NCT05563012Phase 2Recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Sep 2022
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in gastric adenocarcinoma, sponsored by Renmin Hospital of Wuhan University. Started Sep 2022; status: recruiting.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT05563012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05563012.